In this issue:
Leukaemia selection
Sequential imatinib-based approach for Ph+ ALL
Consensus guidelines for hairy cell leukaemia
Long-term follow-up of stopping imatinib in CML (STIM1)
Lymphoma selection
Lugano response criteria refinement for immunomodulators
Cancer-related fatigue in Hodgkin’s lymphoma
Inferior PFS after SCT for double-expressor and double-hit lymphomas
Mediastinal gray zone lymphoma
DLBCL with testicular involvement in the rituximab era
R-hyperCVAD not feasible as pre-HSCT induction in MCL
RBAC500 for induction in elderly MCL
Please login below to download this issue (PDF)